Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077078 | 1.00 | LAP3 (0.45) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL10078080 | 0.88 | DPP4 (0.38) | LAP3ANPEPRNPEPDNPEPMMP2 | |
| SCHEMBL10074155 | 0.87 | LAP3 (0.46) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL10074145 | 0.86 | MMP2 (0.50) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL10074349 | 0.86 | MMP2 (0.50) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL6873752 | 0.83 | LAP3 (0.49) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL6873314 | 0.83 | LAP3 (0.49) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL10074277 | 0.82 | LAP3 (0.45) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL6873883 | 0.81 | LAP3 (0.51) | LAP3ANPEPRNPEPDNPEPMETAP2 | |
| SCHEMBL10074275 | 0.79 | LAP3 (0.50) | LAP3ANPEPRNPEPDNPEPMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | LAP3 186/4885ANPEP 36/4885RNPEP 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.